Search

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

European Affairs

Advocating & collaborating for hematologyEHA serves as the face and voice of hematology and hematology professionals in Europe.

Read more

Priority Points System

The Priority Points System is designed to recognize sponsors’ investment and continuous support for EHA activities, and are allocated for each sponsorship program and/or item.

Read more

EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia

Dates: April 12-14, 2018
Location: Barcelona, Spain
Chair: N Gökbuget
Co-chairs: R Bassan, H Dombret, A Fielding, R Foà, D Hoelzer, JM Ribera

EHA and the EHA Scientific Working Group on Acute Lymphoblastic Leukemia are organizing their second EHA-SWG Scientific Meeting on Acute Lymphoblastic Leukemia.…

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

New HemaSphere publication on IVDR implementation

The In Vitro Diagnostic medical devices Regulation (IVDR), which came in to force in May 2022 with the objective of safeguarding the quality and safety of diagnostic tests in the EU, has a major impact on commercially available IVDs (CEIVDs) and…

Read more

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more